Mark Ratain
Mark Ratain
Leon O. Jacobson Professor of Medicine, The University of Chicago
Verified email at
Cited by
Cited by
Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer
EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, ...
New England Journal of Medicine 363 (18), 1693-1703, 2010
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
MJ Ratain, TIM Eisen, WM Stadler, KT Flaherty, SB Kaye, GL Rosner, ...
Journal of Clinical Oncology 24 (16), 2505-2512, 2006
Tumour heterogeneity in the clinic
PL Bedard, AR Hansen, MJ Ratain, LL Siu
Nature 501 (7467), 355-364, 2013
Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan
F Innocenti, SD Undevia, L Iyer, P Xian Chen, S Das, M Kocherginsky, ...
Journal of Clinical Oncology 22 (8), 1382-1388, 2004
UGT1A1* 28 polymorphism as a determinant of irinotecan disposition and toxicity
L Iyer, S Das, L Janisch, M Wen, J Ramirez, T Karrison, GF Fleming, ...
The pharmacogenomics journal 2 (1), 43-47, 2002
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metaboliteá…
L Iyer, CD King, PF Whitington, MD Green, SK Roy, TR Tephly, ...
The Journal of clinical investigation 101 (4), 847-854, 1998
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
T Eisen, T Ahmad, KT Flaherty, M Gore, S Kaye, R Marais, I Gibbens, ...
British journal of cancer 95 (5), 581-586, 2006
Perceptions of cancer patients and their physicians involved in phase I trials.
C Daugherty, MJ Ratain, E Grochowski, C Stocking, E Kodish, R Mick, ...
Journal of Clinical Oncology 13 (5), 1062-1072, 1995
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea
E Gupta, TM Lestingi, R Mick, J Ramirez, EE Vokes, MJ Ratain
Cancer research 54 (14), 3723-3725, 1994
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer
R Kurzrock, SI Sherman, DW Ball, AA Forastiere, RB Cohen, R Mehra, ...
Journal of Clinical Oncology 29 (19), 2660, 2011
Measuring financial toxicity as a clinically relevant patient‐reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST)
JA De Souza, BJ Yap, K Wroblewski, V Blinder, FS Ara˙jo, FJ Hlubocky, ...
Cancer 123 (3), 476-484, 2017
Phenotype‐genotype correlation of in vitro SN‐38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism
L Iyer, D Hall, S Das, MA Mortell, J RamÝrez, S Kim, A Di Rienzo, ...
Clinical Pharmacology & Therapeutics 65 (5), 576-582, 1999
Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors
JJ Luke, JM Lemons, TG Karrison, SP Pitroda, JM Melotek, Y Zha, ...
Journal of Clinical Oncology 36 (16), 1611, 2018
The development of a financial toxicity patient‐reported outcome in cancer: the COST measure
JA De Souza, BJ Yap, FJ Hlubocky, K Wroblewski, MJ Ratain, D Cella, ...
Cancer 120 (20), 3245-3253, 2014
Oral chemotherapy: rationale and future directions.
MD DeMario, MJ Ratain
Journal of clinical oncology 16 (7), 2557-2567, 1998
Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung
MJ Ratain, LS Kaminer, JD Bitran, RA Larson, MM Le Beau, C Skosey, ...
Pharmacogenomics: challenges and opportunities
DM Roden, RB Altman, NL Benowitz, DA Flockhart, KM Giacomini, ...
Annals of internal medicine 145 (10), 749-757, 2006
Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066
EL Kwak, DR Camidge, J Clark, GI Shapiro, RG Maki, MJ Ratain, ...
Journal of Clinical Oncology 27 (15_suppl), 3509-3509, 2009
The pharmacogenetics research network: from SNP discovery to clinical drug response
KM Giacomini, CM Brett, RB Altman, NL Benowitz, ME Dolan, ...
Clinical Pharmacology & Therapeutics 81 (3), 328-345, 2007
Pharmacokinetic variability of anticancer agents
SD Undevia, G Gomez-Abuin, MJ Ratain
Nature Reviews Cancer 5 (6), 447-458, 2005
The system can't perform the operation now. Try again later.
Articles 1–20